The solution should be clear to pink, free of particles, and without unusual cloudiness or dramatic color changes beyond the expected B12 pink
2000;279(3):E501 to 507
These animal results generated significant excitement and justified moving to human trials
Finally, a commenter suggested that a combined C-code be created to pair 64568 with C1827 ( Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller )
With respect to the newness criterion at 419.66(b)(1), FDA granted the applicant 510(k) clearance for the Axoguard HA+ Nerve Protector TM on April 7, 2023, and then granted a second 510(k) clearance for an expanded indication on October 12, 2023
That distinction targeted fat pathway versus systemic GH-axis stimulation is the core of why researchers choose one over the other, and it shapes everything from their evidence base to their regulatory status